Le LÚzard
Classified in: Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results


DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Thursday, March 2, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2022 operating and financial results. In advance of the call on March 2, 2023, DermTech will issue its fourth-quarter 2022 earnings press release.

For participants interested in asking questions during the teleconference, please register using the following link. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during the live teleconference, but advance registration is advised.

Conference Call Registration

For participants interested in listening only, please register for the webcast using the following link.

Webcast Registration

For those unable to participate in the live call and webcast, a webcast replay will be available on the Company's website shortly after the conclusion of the call.

About DermTech

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech's mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using its Smart Stickerstm. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "outlook," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost- effectiveness, commercialization and adoption of DermTech's products and the market opportunity for these products, DermTech's positioning and potential revenue growth, financial outlook and future financial performance, ability to maintain or improve its operating efficiency, implications and interpretations of any study results, expectations regarding reimbursement or cash collection patterns from Medicare from commercial payors and related billing practices or number of covered lives, and DermTech's ability to expand its product offerings and develop pipeline products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech's ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech's tests; (4) the reimbursement of DermTech's tests by Medicare and commercial payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech's products; (6) DermTech's ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech's products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in the "Risk Factors" section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the "SEC"), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.


These press releases may also interest you

at 12:45
WHY:áRosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telephone and Data Systems, Inc. between May 6, 2022 and November 3, 2022, both dates inclusive (the "Class Period"), of the important July 3, 2023 lead...

at 12:43
WHY:áRosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADSs") of TAL Education Group between June 14, 2022 and March 14, 2023, both dates inclusive (the "Class Period"), of the important May 30,...

at 08:58
His Excellency Gu­ni Th. Jˇhannesson, President of Iceland and First Lady, Eliza Reid are scheduled for an official visit and will be in Ottawa on Sunday May 28. This will be the first Icelandic state visit to Canada since 2000....

27 mai 2023
PattieSwap a new decentralized exchange (DEX), has officially launched its platform on the Binance Smart Chain. The platform allows users to trade and swap cryptocurrencies without the need for intermediaries and aims to provide a secure, reliable,...

27 mai 2023
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Icahn Enterprises L.P. between August 2, 2018 and May 9, 2023, both dates inclusive (the "Class Period"), of the important July 10, 2023 lead plaintiff...

27 mai 2023
Shareholder rights law firm Julie & Holleman LLP is investigating the proposed $30 per share acquisition of Franchise Group, Inc. by the company's senior management team. The firm is concerned about the price being offered as well as potential...



News published on and distributed by: